Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amina Jindani

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Tuberculosis (Edinburgh, Scotland)|April 13, 2010
Professor D A Mitchison: 60 years of contributions to the chemotherapy of tuberculosisPhilip D Butcher, Amina Jindani
Tuberculosis (Edinburgh, Scotland)|April 13, 2010
Challenges to the development of new drugs and regimens for tuberculosisAmina Jindani, George E Griffin
American Journal of Respiratory and Critical Care Medicine|January 10, 2003
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 daysAmina Jindani, Caroline J Doré, Denis A Mitchison
The Journal of Infectious Diseases|May 12, 2007
Isoniazid activity is terminated by bacterial persistenceDenis A Mitchison, Amina Jindani, Geraint R Davies, et al.
BMC Infectious Diseases|April 26, 2017
Predictors of delayed culture conversion among Ugandan patientsDaniel Atwine, Patrick Orikiriza, Ivan Taremwa, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis InfectionJennifer E Hibma, Kendra K Radtke, Susan E Dorman, et al.
BMC Medicine|March 30, 2017
Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trialAdam A Witney, Anna L E Bateson, Amina Jindani, et al.
JAMA|April 14, 2011
Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trialChristian Lienhardt, Sharlette V Cook, Marcos Burgos, et al.
Antimicrobial Agents and Chemotherapy|November 6, 2013
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patientsSimbarashe P Zvada, Paolo Denti, Frederick A Sirgel, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentineSimbarashe P Zvada, Paolo Denti, Hennie Geldenhuys, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Tuberculosis (Edinburgh, Scotland)|April 13, 2010
Professor D A Mitchison: 60 years of contributions to the chemotherapy of tuberculosisPhilip D Butcher, Amina Jindani
Tuberculosis (Edinburgh, Scotland)|April 13, 2010
Challenges to the development of new drugs and regimens for tuberculosisAmina Jindani, George E Griffin
American Journal of Respiratory and Critical Care Medicine|January 10, 2003
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 daysAmina Jindani, Caroline J Doré, Denis A Mitchison
The Journal of Infectious Diseases|May 12, 2007
Isoniazid activity is terminated by bacterial persistenceDenis A Mitchison, Amina Jindani, Geraint R Davies, et al.
BMC Infectious Diseases|April 26, 2017
Predictors of delayed culture conversion among Ugandan patientsDaniel Atwine, Patrick Orikiriza, Ivan Taremwa, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis InfectionJennifer E Hibma, Kendra K Radtke, Susan E Dorman, et al.
BMC Medicine|March 30, 2017
Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trialAdam A Witney, Anna L E Bateson, Amina Jindani, et al.
JAMA|April 14, 2011
Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trialChristian Lienhardt, Sharlette V Cook, Marcos Burgos, et al.
Antimicrobial Agents and Chemotherapy|November 6, 2013
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patientsSimbarashe P Zvada, Paolo Denti, Frederick A Sirgel, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentineSimbarashe P Zvada, Paolo Denti, Hennie Geldenhuys, et al.
Pageof 2